{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:59:14Z","timestamp":1790330354636,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23AA2003"],"award-info":[{"award-number":["23AA2003"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Evidence Based Medicine"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Although concerns have been raised that glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101RAs) may increase the risk of bowel obstruction or ileus, evidence remains inconclusive. In this context of uncertainty, we examined the frequency and determinants of GLP\u20101RA discontinuation after hospitalization for bowel obstruction\/ileus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using a nationwide Japanese health insurance claims database (DeSC). We identified individuals aged \u226518 years with type 2 diabetes who were hospitalized for bowel obstruction\/ileus between 2016 and 2023 while receiving GLP\u20101RA therapy. The primary outcome was GLP\u20101RA discontinuation, defined as no prescription at discharge or within 6 months of discharge. Factors potentially associated with discontinuation were grouped into (1) general factors, (2) severity of bowel obstruction\/ileus, and (3) potential therapeutic benefit of GLP\u20101RA therapy. Risk differences (RDs) for discontinuation were estimated using multivariable linear regression with robust standard errors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      GLP\u20101RAs were discontinued in 86 (43.9%) of the 196 patients analyzed. Multivariable analysis revealed that surgery for bowel obstruction during hospitalization (RD = 32.1%; 95% confidence interval [CI] 11.2% to 53.0%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.003), longer length of stay (\u226515 days vs. \u22647 days; RD = 32.4%; 95% CI 11.2% to 53.5%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.003), and heart failure (RD = 17.6%; 95% CI 2.1% to 33.2%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.027) were associated with GLP\u20101RA discontinuation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nearly half of the patients discontinued GLP\u20101RAs after a bowel obstruction\/ileus event. While GLP\u20101RAs were more likely to be discontinued after severe events, their potential therapeutic benefits appeared less frequently considered in continuation decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jebm.70164","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:51:11Z","timestamp":1783939871000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discontinuation of Glucagon\u2010Like Peptide\u20101 Receptor Agonists After Bowel Obstruction or Ileus: A Nationwide, Real\u2010World, Database Study"],"prefix":"10.1111","volume":"19","author":[{"given":"Yuichiro","family":"Matsuo","sequence":"first","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics Graduate School of Medicine The University of Tokyo  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Prevention of Diabetes and Lifestyle\u2010Related Diseases Graduate School of Medicine The University of Tokyo  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Gastroenterology Center Cancer Institute Hospital of Japanese Foundation for Cancer Research  Tokyo Japan"},{"name":"Department of Healthcare Quality Assessment Graduate School of Medicine The University of Tokyo  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yasunaga","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics Graduate School of Medicine The University of Tokyo  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00203-5"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410"},{"key":"e_1_2_7_4_1","unstructured":"Pharmaceuticals and Medical Devices Agency \u201cPharmaceuticals and Medical Devices Safety Information \u201d No. 291 June 2012 Accessed June 2025 https:\/\/www.pmda.go.jp\/files\/000153459.pdf."},{"key":"e_1_2_7_5_1","unstructured":"European Medicines Agency \u201cPharmacovigilance Risk Assessment Committee (PRAC) \u201dMinutes of the Meeting \u20147\u201310 January 2013 Accessed June 2025 https:\/\/www.ema.europa.eu\/en\/documents\/minutes\/minutes\u2010prac\u2010meeting\u20107\u201010\u2010january\u20102013_en.pdf."},{"key":"e_1_2_7_6_1","unstructured":"U.S. Food and Drug Administration \u201cPotential Signals of Serious Risks\/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) \u201d April\u2013June 2022 Accessed June 2025 https:\/\/www.fda.gov\/drugs\/fdas\u2010adverse\u2010event\u2010reporting\u2010system\u2010faers\/april\u2010june\u20102022\u2010potential\u2010signals\u2010serious\u2010risksnew\u2010safety\u2010information\u2010identified\u2010fda\u2010adverse\u2010event."},{"key":"e_1_2_7_7_1","unstructured":"\u201cProduct Information: Victoza Subcutaneous Injection (liraglutide) \u201d Accessed July 2025 https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/620023_2499410G1021_1_12 Updated February2024."},{"key":"e_1_2_7_8_1","unstructured":"\u201cProduct Information: Byetta Subcutaneous Injection Pen (Exenatide) \u201d Accessed July 2025 https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/670227_2499411G1026_2_07 Updated February2023."},{"key":"e_1_2_7_9_1","unstructured":"\u201cProduct Information: Trulicity Subcutaneous Injection Ateos (Dulaglutide) \u201d Accessed July 2025 https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/530471_2499416G1029_1_20 Updated June2025."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2430"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.08.034"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-025-02525-z"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16642"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.06.003"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02799-9"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.16-5-481"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.08.028"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.23.0078"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.12112025"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124100-00005"},{"issue":"6","key":"e_1_2_7_22_1","first-page":"562","article-title":"Case Report: Small Bowel Obstruction After Starting Tirzepatide (Mounjaro)","volume":"110","author":"Morgenthaler L.","year":"2024","journal-title":"American Family Physician"},{"issue":"4","key":"e_1_2_7_23_1","article-title":"GLP\u20101 Receptor Agonists in Diabetes and Obesity: A Case Report and Review of Bowel Obstruction Risks and Management","volume":"17","author":"Jones M.","year":"2025","journal-title":"Cureus"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01800-z"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.37737\/ace.25006"},{"issue":"2","key":"e_1_2_7_28_1","first-page":"190","article-title":"Prevalence of Noncommunicable Diseases in Japan Using a Newly Developed Administrative Claims Database Covering Young, Middle\u2010Aged, and Elderly People","volume":"5","author":"Okada A.","year":"2022","journal-title":"Jma Journal"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwm223"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13172"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15872"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S277676"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4968"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12095"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.00575_13.x"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5812"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-023-08364-4"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.10.005"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S141235"},{"key":"e_1_2_7_42_1","unstructured":"\u201cHighlights of Prescribing Information: Victoza (Liraglutide) Injection for Subcutaneous Use \u201d Accessed August 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/022341s044lbl.pdf. Updated May2025."},{"key":"e_1_2_7_43_1","unstructured":"\u201cVictoza: EPARProduct Information. European Medicines Agency \u201d Accessed June 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/victoza\u2010epar\u2010product\u2010information_en.pdf Updated February2025."}],"container-title":["Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jebm.70164","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jebm.70164","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jebm.70164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:02:17Z","timestamp":1790326937000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jebm.70164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/jebm.70164"],"URL":"https:\/\/doi.org\/10.1111\/jebm.70164","archive":["Portico"],"relation":{},"ISSN":["1756-5383","1756-5391"],"issn-type":[{"value":"1756-5383","type":"print"},{"value":"1756-5391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"2025-10-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70164"}}